Skip to main content
AmigoFish

Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data

From BioCentury This Week · · 42 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

The departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss (https://www.biocentury.com/article/660189) what Vallance’s exit, the appointment of John Healey as Chancellor of the Exchequer and other changes arriving with the new Prime Minister could mean for life sciences in the country. BioCentury’s analysts also discuss an ambitious U.K. data initiative launched this month. The Health Data Research Service is intended to be a single front door (https://www.biocentury.com/article/660154) to all NHS health records, offering large-scale longitudinal health data across diverse populations.

Beyond the U.K., the team turns to companies to watch in Taiwan, what’s next (https://www.biocentury.com/article/660138) for Biogen’s anti-tau therapy, Eli Lilly’s proposed acquisition (https://www.biocentury.com/article/660152) of psychedelics company AtaiBeckley, and the latest changes (https://www.biocentury.com/article/660169) at FDA. This episode of the BioCentury This Week podcast has been brought to you by CBRE (https://www.cbre.com/).

View full story: https://www.biocentury.com/article/660194

#Biotech #LifeSciences #UKBiotech #HealthData #FDA

00:01 - Sponsor Message: CBRE 02:23 - U.K. Leadership Changes 09:21 - U.K. Data Initiative 10:52 - Taiwan Biotech 16:44 - Biogen’s Tau Data 27:18 - Lilly’s Psychedelics Takeout 28:20 - FDA

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)

Back to BioCentury This Week · Report a problem